Latest news with #MartineRothblatt
Globe and Mail
6 hours ago
- Business
- Globe and Mail
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that it will enter today into two Accelerated Share Repurchase ( ASR) agreements with Citibank, N.A. ( Citi) to repurchase an aggregate $1 billion of UTHR common stock. United Therapeutics will repurchase these shares under the $1 billion repurchase program authorized by the company's board of directors and previously announced on July 30, 2025. 'These expeditious agreements reflect our confidence in the intrinsic value of our stock, our upcoming catalysts, and our ability to generate sustained revenue and cash flow growth,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'Our capital allocation philosophy provides us with the flexibility to both invest in our future growth while returning capital to our shareholders, and we remain committed to this balanced approach that will leave us with ample remaining capital on our balance sheet to fulfill our long-term goals.' Under the terms of the ASR agreements, which comprise a $500 million collared and a $500 million uncollared agreement, United Therapeutics will make an aggregate upfront payment of $1 billion to Citi on August 4, 2025. United Therapeutics will receive an initial delivery of shares representing approximately 75% of the total shares anticipated to be repurchased under the uncollared ASR agreement ( Uncollared ASR), plus approximately 50% of the total shares anticipated to be repurchased under the collared ASR agreement ( Collared ASR), in each case, measured based on the closing stock price of UTHR common stock on August 1, 2025. United Therapeutics also will receive an additional delivery of shares under the Collared ASR prior to final settlement following the completion of an agreed-upon hedging period. Uncollared ASR. The final number of shares that United Therapeutics will ultimately repurchase pursuant to the Uncollared ASR will be based on the average of the daily volume-weighted average price per share of UTHR common stock during the term of the Uncollared ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the Uncollared ASR. Final settlement of the Uncollared ASR agreement is expected to be in the fourth quarter of 2025. Collared ASR. The final number of shares that United Therapeutics will ultimately repurchase pursuant to the Collared ASR will be determined based on the average of the daily volume-weighted average price per share of UTHR common stock during the term of the Collared ASR, less a discount and subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments, pursuant to the terms and conditions of the Collared ASR. Final settlement of the Collared ASR agreement is expected to be in the first quarter of 2026. At final settlement of the ASR agreements, United Therapeutics may be entitled to receive additional shares of its common stock, or, in certain limited circumstances, be required to make cash payment to Citi or, if United Therapeutics elects, deliver shares to Citi. At July 30, 2025, United Therapeutics had approximately 45.2 million shares outstanding. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation ( PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our confidence in our near-term prospects, the intrinsic value of our stock, and our upcoming catalysts; the growth of our business, including our ability to generate sustained revenue and cash flow growth; the benefits of the share repurchase to shareholders; our plan to enter into the ASR agreements; the number of shares to be repurchased under the ASR agreements; the timing and manner of the final settlement under the ASR agreements; our views regarding whether our remaining capital will be sufficient to fulfill our long-term goals and to invest in future growth; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of August 1, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
Globe and Mail
2 days ago
- Business
- Globe and Mail
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in the second quarter of 2024. 'Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available. 'Equally, our strong financial position, confidence in these upcoming catalysts, and belief in our share price potential has led our Board of Directors to authorize up to $1 billion in share repurchases, affirming our commitment to a robust and balanced capital allocation philosophy.' Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, 'We're proud of the continued record performance for Tyvaso DPI, a best-in-class treprostinil dry powder inhaler that allows the flexibility of one breath per cartridge, four times a day, with low inspiratory effort. Further, no other commercially available treprostinil dry powder inhaler has been clinically studied with published data at higher doses 1,2 or prescribed by more physicians to more patients than Tyvaso DPI. 'We expect continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.' Second Quarter 2025 Financial Results Key financial highlights include (dollars in millions, except per share data): Revenues The table below presents the components of total revenues (dollars in millions): Three Months Ended June 30, Dollar Change Percentage Change 2025 2024 Net product sales: Tyvaso DPI ®(1) $ 315.2 $ 258.3 $ 56.9 22 % Nebulized Tyvaso ®(1) 154.4 139.9 14.5 10 % Total Tyvaso 469.6 398.2 71.4 18 % Remodulin ®(2) 134.7 147.3 (12.6 ) (9 )% Orenitram ® 123.9 107.1 16.8 16 % Unituxin ® 58.4 51.7 6.7 13 % Adcirca ® 6.5 5.7 0.8 14 % Other 5.5 4.9 0.6 12 % Total revenues $ 798.6 $ 714.9 $ 83.7 12 % (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity ® Pump. Total Tyvaso revenues grew by 18 percent to $469.6 million in the second quarter of 2025, compared to $398.2 million in the second quarter of 2024. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $54.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act ( IRA). The growth in Nebulized Tyvaso revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $10.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA. The table below presents the breakdown of total revenues between the United States and rest-of-world ( ROW) (in millions): Three Months Ended June 30, 2025 2024 U.S. ROW Total U.S. ROW Total Net product sales: Tyvaso DPI (1) $ 314.8 $ 0.4 $ 315.2 $ 258.3 $ — $ 258.3 Nebulized Tyvaso (1) 140.5 13.9 154.4 130.2 9.7 139.9 Total Tyvaso 455.3 14.3 469.6 388.5 9.7 398.2 Remodulin (2) 113.7 21.0 134.7 122.5 24.8 147.3 Orenitram 123.9 — 123.9 107.1 — 107.1 Unituxin 55.4 3.0 58.4 46.8 4.9 51.7 Adcirca 6.5 — 6.5 5.7 — 5.7 Other 5.0 0.5 5.5 4.6 0.3 4.9 Total revenues $ 759.8 $ 38.8 $ 798.6 $ 675.2 $ 39.7 $ 714.9 (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Expenses Cost of sales. The table below summarizes cost of sales by major category (dollars in millions): (1) See Share-based compensation below. Cost of sales, excluding share-based compensation. Cost of sales for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to an increase in: (1) royalty expense resulting from a growth in revenues; and (2) reserve expense resulting from increased production. Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions): 2025 2024 Category: External research and development (1) $ 62.4 $ 49.4 $ 13.0 26 % Internal research and development (2) 55.9 44.5 11.4 26 % Share-based compensation expense (3) 8.1 8.6 (0.5 ) (6 )% Other (4) 7.6 37.1 (29.5 ) (80 )% Total research and development expense $ 134.0 $ 139.6 $ (5.6 ) (4 )% (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. Research and development, excluding share-based compensation. Research and development expense for the three months ended June 30, 2025 decreased as compared to the same period in 2024, primarily due to $36.0 million in upfront non-refundable license payments for drug delivery device technologies in 2024, partially offset by: (1) increased expenditures in 2025 related to manufactured organ and organ alternative projects; and (2) a $5.0 million milestone payment made in 2025 for drug delivery device technologies. Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions): 2025 2024 Category: General and administrative (1) $ 131.1 $ 113.0 $ 18.1 16 % Impairment of property, plant, and equipment ( PP&E) 21.7 — 21.7 NM (2) Sales and marketing 31.0 25.4 5.6 22 % Share-based compensation expense (3) 28.7 39.2 (10.5 ) (27 )% Total selling, general, and administrative expense $ 212.5 $ 177.6 $ 34.9 20 % (1) Excluding impairment of PP&E. See Impairment of PP&E section below. (2) Calculation is not meaningful. (3) See Share-based compensation below. General and administrative, excluding impairment of PP&E and share-based compensation. General and administrative expense for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to: (1) personnel expense due to growth in headcount; and (2) legal expenses related to litigation matters. Impairment of PP&E. During the three months ended June 30, 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E. Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions): 2025 2024 Category: Stock options $ 11.1 $ 8.1 $ 3.0 37 % Restricted stock units 26.0 19.2 6.8 35 % Share tracking awards plan ( STAP) — 21.9 (21.9 ) (100 )% Employee stock purchase plan 0.7 0.5 0.2 40 % Total share-based compensation expense $ 37.8 $ 49.7 $ (11.9 ) (24 )% The decrease in share-based compensation expense for the three months ended June 30, 2025, as compared to the same period in 2024, was primarily due to a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025. Income tax expense. Income tax expense for the three months ended June 30, 2025 and 2024 was $98.9 million and $77.2 million, respectively. Our effective income tax rate ( ETR) for the three months ended June 30, 2025 and 2024 was 24 percent and 22 percent, respectively. Our ETR for the three months ended June 30, 2025 increased compared to our ETR for the three months ended June 30, 2024, primarily due to a decrease in excess tax benefits from share-based compensation. Webcast We will host a webcast to discuss our second quarter 2025 financial results on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation ( PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our share repurchase program, the anticipated timing and outcome of the TETON 2 and TETON 1 clinical trials of Nebulized Tyvaso in idiopathic pulmonary fibrosis, including potential for these studies to improve options for patients with this disease; the anticipated readout of the ADVANCE OUTCOMES clinical trial of ralinepag; our near- to medium-term catalysts positioned for sustained long-term growth; our expectation of continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. ADCIRCA is a registered trademark of Eli Lilly and Company. Three Months Ended June 30, 2025 2024 (Unaudited) Total revenues $ 798.6 $ 714.9 Operating expenses: Cost of sales 87.6 77.8 Research and development 134.0 139.6 Selling, general, and administrative 212.5 177.6 Total operating expenses 434.1 395.0 Operating income 364.5 319.9 Interest income 51.3 46.2 Interest expense (7.3 ) (11.6 ) Other (expense) income, net (0.1 ) 0.8 Total other income, net 43.9 35.4 Income before income taxes 408.4 355.3 Income tax expense (98.9 ) (77.2 ) Net income $ 309.5 $ 278.1 Net income per common share: Basic $ 6.86 $ 6.26 Diluted $ 6.41 $ 5.85 Weighted average number of common shares outstanding: Basic 45.1 44.4 Category: Earnings
Business Wire
2 days ago
- Business
- Business Wire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended June 30, 2025, driven by continued double-digit year-over-year revenue growth in key products such as Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. Total revenues in the second quarter of 2025 grew 12 percent year-over-year to a record $798.6 million, compared to $714.9 million in the second quarter of 2024. 'Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business,' said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. 'We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available. 'Equally, our strong financial position, confidence in these upcoming catalysts, and belief in our share price potential has led our Board of Directors to authorize up to $1 billion in share repurchases, affirming our commitment to a robust and balanced capital allocation philosophy.' Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, 'We're proud of the continued record performance for Tyvaso DPI, a best-in-class treprostinil dry powder inhaler that allows the flexibility of one breath per cartridge, four times a day, with low inspiratory effort. Further, no other commercially available treprostinil dry powder inhaler has been clinically studied with published data at higher doses 1,2 or prescribed by more physicians to more patients than Tyvaso DPI. 'We expect continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.' Second Quarter 2025 Financial Results Key financial highlights include (dollars in millions, except per share data): Revenues The table below presents the components of total revenues (dollars in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity ® Pump. Expand Total Tyvaso revenues grew by 18 percent to $469.6 million in the second quarter of 2025, compared to $398.2 million in the second quarter of 2024. The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $54.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in Tyvaso DPI quantities sold was primarily due to continued growth in the number of patients following the product's launch, including growth in utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA). The growth in Nebulized Tyvaso revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The growth in Orenitram revenues resulted primarily from an increase in quantities sold of $10.6 million and, to a lesser extent, a price increase, partially offset by higher gross-to-net revenue deductions. The increase in quantities sold was driven, at least in part, by increased commercial utilization following the implementation of the Medicare Part D benefit redesign under the IRA. The table below presents the breakdown of total revenues between the United States and rest-of-world (ROW) (in millions): (1) Net product sales include both the drug product and the respective inhalation device. (2) Net product sales include sales of infusion devices, including the Remunity Pump. Expand Expenses Cost of sales. The table below summarizes cost of sales by major category (dollars in millions): (1) See Share-based compensation below. Expand Cost of sales, excluding share-based compensation. Cost of sales for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to an increase in: (1) royalty expense resulting from a growth in revenues; and (2) reserve expense resulting from increased production. Research and development. The table below summarizes the nature of research and development expense by major expense category (dollars in millions): (1) External research and development primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before FDA approval of the relevant product. (2) Internal research and development primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before FDA approval, and internal facilities-related expenses, including depreciation, related to research and development activities. (3) See Share-based compensation below. (4) Other primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations. Expand Research and development, excluding share-based compensation. Research and development expense for the three months ended June 30, 2025 decreased as compared to the same period in 2024, primarily due to $36.0 million in upfront non-refundable license payments for drug delivery device technologies in 2024, partially offset by: (1) increased expenditures in 2025 related to manufactured organ and organ alternative projects; and (2) a $5.0 million milestone payment made in 2025 for drug delivery device technologies. Selling, general, and administrative. The table below summarizes selling, general, and administrative expense by major category (dollars in millions): (1) Excluding impairment of PP&E. See Impairment of PP&E section below. (2) Calculation is not meaningful. (3) See Share-based compensation below. Expand General and administrative, excluding impairment of PP&E and share-based compensation. General and administrative expense for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to: (1) personnel expense due to growth in headcount; and (2) legal expenses related to litigation matters. Impairment of PP&E. During the three months ended June 30, 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E. Share-based compensation. The table below summarizes share-based compensation expense by major category (dollars in millions): The decrease in share-based compensation expense for the three months ended June 30, 2025, as compared to the same period in 2024, was primarily due to a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025. Income tax expense. Income tax expense for the three months ended June 30, 2025 and 2024 was $98.9 million and $77.2 million, respectively. Our effective income tax rate (ETR) for the three months ended June 30, 2025 and 2024 was 24 percent and 22 percent, respectively. Our ETR for the three months ended June 30, 2025 increased compared to our ETR for the three months ended June 30, 2024, primarily due to a decrease in excess tax benefits from share-based compensation. Webcast We will host a webcast to discuss our second quarter 2025 financial results on Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast can be accessed live via our website at An investor presentation is available now, and after the webcast a replay of the webcast will also be available, at the same location on our website. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here: Forward-Looking Statements Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our share repurchase program, the anticipated timing and outcome of the TETON 2 and TETON 1 clinical trials of Nebulized Tyvaso in idiopathic pulmonary fibrosis, including potential for these studies to improve options for patients with this disease; the anticipated readout of the ADVANCE OUTCOMES clinical trial of ralinepag; our near- to medium-term catalysts positioned for sustained long-term growth; our expectation of continued double digit revenue growth for Tyvaso and total revenues well into the future through strong commercial execution of our existing product portfolio coupled with the potential for our late-stage pipeline in pulmonary fibrosis and pulmonary hypertension; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 30, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason. ORENITRAM, REMODULIN, REMUNITY, TYVASO, TYVASO DPI, and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. ADCIRCA is a registered trademark of Eli Lilly and Company. SELECTED CONSOLIDATED BALANCE SHEET DATA (Unaudited, in millions) June 30, 2 025 Cash, cash equivalents, and marketable investments $ 4,966.4 Total assets 7,908.0 Total liabilities 734.4 Total stockholders' equity 7,173.6 Expand Category: Earnings
Yahoo
03-06-2025
- Health
- Yahoo
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
The Academy of Scholars Symposium and Elmezzi Graduate School Commencement celebrate and spotlight the importance of translational biomedical research MANHASSET, N.Y., June 03, 2025--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. "The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration," said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. "The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies." Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. "Physician-scientists produce the innovations and discoveries that make a healthier world," said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. "Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics." To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on Contacts Julianne Mosher Allen516-880-4824jmosherallen@ Sign in to access your portfolio
Business Wire
03-06-2025
- Health
- Business Wire
Leaders in Medicine and Science Celebrate Innovation at the Feinstein Institutes During Two Annual Academic Events
MANHASSET, N.Y.--(BUSINESS WIRE)--Top physician-scientists gathered on Long Island for a two-day celebration of medical research and achievement hosted by Northwell Health's Feinstein Institutes for Medical Research. On May 21, the Feinstein Academy of Scholars Symposium, an integrated network of researchers and scholars who share a passion for revolutionizing translational research, hosted its 8 th annual symposium at the Oheka Castle, Huntington, NY. The next day, at the Feinstein Institutes in Manhasset, NY, the 2025 commencement ceremony of the Elmezzi Graduate School of Molecular Medicine took place, where two new PhDs were conferred along with two honorary degrees given to Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine and Martine Rothblatt, PhD, JD, CEO of United Therapeutics Corporation. 'The Feinstein Institutes' commitment to translational research was evident throughout this two-day celebration,' said Bettie M. Steinberg, PhD, interim dean of the Elmezzi Graduate School of Molecular Medicine and professor in the Feinstein Institutes Institute of Molecular Medicine. 'The symposium highlighted cutting-edge discoveries poised to move from the lab to the clinic, while the Elmezzi graduates represent the next generation of scientists dedicated to turning scientific advancements into tangible therapies.' Meeting of minds at the Feinstein Academy of Scholars Symposium Members of the Academy include recipients of honorary doctoral degrees from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers, recipients of the Cerami, Ross and Advancing Women in Science and Medicine (AWSM) prizes, and researchers from the Feinstein Institutes. This year's featured keynote speakers included: Tobias Janowitz, MD, PhD, associate professor and Cancer Center Program Leader at Cold Spring Harbor Laboratory, provided an overview of the current research on systemic signaling in paraneoplasia, emphasizing the importance of this area of study. Lopa Mishra, MD, co-director and professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Susan and Herman Merinoff Distinguished Chair in Translational Medicine, explained how specific environmental toxins contribute to liver cancer and outlined methods to selectively target these cancer cells. Akiko Iwasaki, PhD, Sterling Professor of Immunology at Yale University School of Medicine, spoke about examining the role of immune dysregulation in the pathogenesis of post-acute infection syndrome. Douglas F. Nixon, MD, PhD, Karches Family Professor in Translational Research and director and professor, Institute of Translational Research at the Feinstein Institutes, spoke about human endogenous retroviruses (HERVs) are part of our non-coding DNA and that our own genomes can impact our health and disease. Max Brenner, MD, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, spoke about an Elmezzi scholar's scientific journey stemming from the classroom to the clinic and the lab. Linda Van Aelst, PhD, professor at Cold Spring Harbor Laboratory, discussed the intricate involvement of Rho regulators in synapse formation and dysfunction. Celebrating the future of medical research On May 22, two clinicians were conferred their PhD during the Elmezzi Graduate School of Molecular Medicine graduation. This unique PhD program is for physicians (MDs) who wish to pursue careers in biomedical research. During the program, Elmezzi students conduct research in Feinstein Institutes laboratories to advance medical research and pursue new therapeutic approaches and diagnostic tools. The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from the Thomas and Jeanne Elmezzi Foundation. Two honorary degrees were bestowed at the Elmezzi commencement. The first to Dr. Iwasaki for her research on immune defense against viruses at mucosal surfaces, and to Dr. Rothblatt for her contributions to new treatments for rare diseases and advances in organ transplants. In addition, she was the creator of the satellite radio company SiriusXM. This year's graduates include: Willians Tambo Ayol, MD, investigated the role of microvascular dysfunction in cognitive impairment and dementia, and explored the therapeutic potential of the diving reflex's protective mechanisms against cerebral hypoperfusion. Santhoshi Poonacha Palandira, MBBS, MS, MCh, applied optogenetics to neuromodulate brainstem nuclei to regulate inflammation. She also identified celiac-superior mesenteric ganglion complex in the abdomen and identified it as a new therapeutic target for noninvasive bioelectronic therapies to treat inflammation with a translational potential. 'Physician-scientists produce the innovations and discoveries that make a healthier world,' said Kevin J. Tracey, MD, president and CEO of Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'Elmezzi graduates are committed to career paths that will lead to new therapies and diagnostics.' To find out more about the Elmezzi Graduate School of Molecular Medicine and its programs, click here. About The Elmezzi Graduate School of Molecular Medicine: The Elmezzi Graduate School of Molecular Medicine at Northwell Health offers MDs an accelerated PhD three-year program emphasizing translational research. Its mission is to provide academic training for physicians to discover and understand the causes of human diseases and to rapidly and effectively translate this information into diagnostic and therapeutic solutions. The program started in 1994 and is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation. To date, more than 50 physician-scientists have graduated from the prestigious program. The Elmezzi School of Molecular Medicine is accredited by the WASC Senior College and University Commission (WSCUC). For more information, click here. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
